Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

致癌物含量超标，Aurobindo正在美国召回近50万瓶抗血压药

2019-01-28 MedSci MedSci原创

召回抗血压药致癌物
关注

据"经济时报"周日报道，在美国食品和药物管理局发现Aurobindo公司抗血压药中的致癌物N-亚硝基二甲胺的含量超过临时可接受的每日摄入量0.083%后，Aurobindo正在美国召回大约50万瓶降血压药物。

据"经济时报"周日报道，在美国食品和药物管理局发现Aurobindo公司抗血压药中的致癌物N-亚硝基二甲胺的含量超过临时可接受的每日摄入量0.083%后，Aurobindo在美国召回了大约50万瓶降血压药物。

据FDA称，该公司正在召回162301瓶氨氯地平和缬沙坦片，312095瓶缬沙坦和氢氯噻嗪片和20604瓶缬沙坦片。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1370970, encodeId=a9d813e097050, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448833, encodeId=d2f11448833bc, content=<a href='/topic/show?id=8dde8651197' target=_blank style='color:#2F92EE;'>#致癌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86511, encryptionId=8dde8651197, topicName=致癌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3005440223, createdName=qjddjq, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469128, encodeId=91781469128d8, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489264, encodeId=771f1489264de, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359422, encodeId=2d02359422ab, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jan 28 10:48:36 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2019-01-30 jambiya

    #致癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1370970, encodeId=a9d813e097050, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448833, encodeId=d2f11448833bc, content=<a href='/topic/show?id=8dde8651197' target=_blank style='color:#2F92EE;'>#致癌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86511, encryptionId=8dde8651197, topicName=致癌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3005440223, createdName=qjddjq, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469128, encodeId=91781469128d8, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489264, encodeId=771f1489264de, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359422, encodeId=2d02359422ab, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jan 28 10:48:36 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2019-01-30 qjddjq

    #致癌物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1370970, encodeId=a9d813e097050, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448833, encodeId=d2f11448833bc, content=<a href='/topic/show?id=8dde8651197' target=_blank style='color:#2F92EE;'>#致癌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86511, encryptionId=8dde8651197, topicName=致癌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3005440223, createdName=qjddjq, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469128, encodeId=91781469128d8, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489264, encodeId=771f1489264de, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359422, encodeId=2d02359422ab, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jan 28 10:48:36 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2019-01-30 xiaogang319

    #IND#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1370970, encodeId=a9d813e097050, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448833, encodeId=d2f11448833bc, content=<a href='/topic/show?id=8dde8651197' target=_blank style='color:#2F92EE;'>#致癌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86511, encryptionId=8dde8651197, topicName=致癌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3005440223, createdName=qjddjq, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469128, encodeId=91781469128d8, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489264, encodeId=771f1489264de, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359422, encodeId=2d02359422ab, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jan 28 10:48:36 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2019-01-30 doctorzheng

    #召回#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1370970, encodeId=a9d813e097050, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448833, encodeId=d2f11448833bc, content=<a href='/topic/show?id=8dde8651197' target=_blank style='color:#2F92EE;'>#致癌物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86511, encryptionId=8dde8651197, topicName=致癌物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3005440223, createdName=qjddjq, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469128, encodeId=91781469128d8, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489264, encodeId=771f1489264de, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Wed Jan 30 01:17:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359422, encodeId=2d02359422ab, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jan 28 10:48:36 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2019-01-28 1ddf0692m34(暂无匿称)

    学习了，长知识

    0

相关资讯

召回不可怕 可怕的是不召回

2018年出发不足一月，CFDA（国家食品药品监督管理总局）就发布百余条医疗设备、检验试剂的召回信息，涉及通用电气、西门子、飞利浦、罗氏、强生、雅培、奥林巴斯、贝克曼、爱克发、迈柯唯等多家知名企业。当然，类别都是主动召回。近年来，召回已成为公众熟知的一个名词，而且因牵涉产品质量和安全，不免忧心忡忡。但事实上，企业主动召回，反而体现其对客户和患者安全负责的态度，是一种主动避免问题的行为。相比之下，

5类高血压常用药被召回，所有医疗机构停用！

一、缬沙坦原料药检出微量N-亚硝基二甲胺7月29日，国家药监局新闻发言人介绍浙江华海药业股份有限公司（以下简称华海药业）缬沙坦原料药中检出微量N-亚硝基二甲胺(NDMA)杂质有关情况。在此之前，华海药业已于7月6日向国家药监局报告在用于出口的缬沙坦原料药中检出微量N-亚硝基二甲胺(NDMA)杂质的情况，并采取积极措施主动召回。目前，欧盟等多国药品监管机构认为，NDMA属于2A类致癌物（即动物实验

这5类防晒霜出事了！含进口产品！

日前，国家食品药品监管总局通告，托尼魅力化妆品(深圳)有限公司代理的托尼魅力细腻清爽防晒霜(进口国韩国)，广州澳希亚实业有限公司代理的赫拉水透亲肤防晒液(进口国澳大利亚)等5批次防晒类化妆品不合格。 ​

在缬沙坦召回事件1年多前，FDA已经发现了华海药业的生产问题

在全球召回受污染的心脏药物缬沙坦近2年前，FDA对浙江华海制药厂进行了检查，发现其工厂极少考虑质量控制，并且经常将"ghost peaks"、实验室错误和环境问题归咎于测试结果错误。

关于医疗器械的“召回”，你还应该了解这些

“召回”二字到底意味着什么？医疗企业应该主动召回还是杜绝召回？这一次，我们针对医疗器械行业对不良事件的监测及召回案例，作出一些探讨，让更多人了解医疗器械行业的“召回”。

医疗器械召回：何必谈虎色变

近年，“召回”一词，渐渐成为一个敏感词汇出现在公众视野。这一行为的实施者，除了常见的汽车制造商，还有医疗器械生产商。但如同每逢汽车召回总引发国内民众担忧质量和安全一样，医疗器械召回也常常招致医疗机构忧心忡忡。其实，医疗机构貌似熟悉的“召回”，仍存在陌生或被误读的一面。召回公示背后医疗行业的很多人知道，国家食品药品监督管理总局（下称“国家药监局”），履行着一项重要职能——建立医疗行业问题产品的召

Baidu
map
Baidu
map
Baidu
map